Malignant peritoneal mesothelioma: a review

Area of Science:

• Oncology
• Epidemiology
• Surgical Oncology

Background:

• Mesothelioma is a rare malignancy of serosal membranes, predominantly affecting the pleura and peritoneum.
• Malignant peritoneal mesothelioma (MPM) is strongly associated with asbestos exposure and typically presents with diffuse abdominal spread.
• Nonspecific symptoms and rarity lead to late diagnosis, often when the disease burden is extensive.

Purpose of the Study:

• To review the epidemiology of malignant peritoneal mesothelioma (MPM).
• To discuss current diagnostic strategies for MPM.
• To outline established and developing treatment approaches for MPM.

Main Methods:

• Review of epidemiological data concerning MPM.
• Analysis of diagnostic criteria and challenges for MPM.
• Evaluation of current therapeutic modalities, including cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC).

Main Results:

• MPM is a rare, aggressive cancer with a poor prognosis if untreated, typically fatal within a year.
• Late diagnosis is common due to nonspecific symptoms and disease rarity.
• Cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) is the current standard of care.

Conclusions:

• MPM remains a challenging diagnosis with a universally fatal outcome, often due to abdominal complications.
• Advances in treatment, particularly CRS with HIPEC, represent the mainstay of current therapeutic efforts.
• Further research into systemic therapies is ongoing to improve outcomes for MPM patients.